Secukinumab for the treatment of generalized pustular psoriasis: A case report

Introduction:Generalized pustular psoriasis (GPP) is a rare subtype of psoriasis that manifests as a generalized pustular eruption. Patient concerns:A 31-year-old female was admitted to the hospital in June 2021 with a widespread erythematous, itchy, and scaly rash for a week. The patient has a 10-year history of psoriasis vulgaris. Diagnosis:GPP complicated by a late-stage viral infection and early-stage renal damage. Interventions:Weekly subcutaneous injections of 300 mg of secukinumab for a month, followed by monthly (every 4 weeks) injections of 300 mg of secukinumab for 20 weeks. Outcomes:The symptoms of pustules and erythema were reduced, and the patient reported pain relief soon after the first injection. The patient had no serious adverse reactions during treatment and follow-up. Conclusions:Secukinumab might be an optional treatment strategy for GPP.

Automated summary

This study reports a case of generalized pustular psoriasis (GPP) in a 31-year-old female patient with a 10-year history of psoriasis vulgaris. The patient presented with a widespread erythematous, itchy, and scaly rash and was diagnosed with GPP complicated by a late-stage viral infection and early-stage renal damage. The patient received weekly subcutaneous injections of 300 mg of secukinumab for a month, followed by monthly injections for 20 weeks. The treatment resulted in reduced pustules and erythema, and the patient reported pain relief after the first injection. No serious adverse reactions were observed during treatment and follow-up. Therefore, secukinumab may be an optional treatment strategy for GPP.